Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Post by dt_coreon Sep 07, 2012 9:21am

369 Views

Post# 20330736

BNN Market Call Commentary on HEM

Prakash Hariharan (Front Street Capital) was on BNN Market Call last night talking about HEM. His comments:

* Good company but management has been an issue (disappointing constantly on earnings)

* Just brought in a new CEO, who was the founder. Views this as a positive move

* Thinks that the change in management could result in several possibilities including but not limited too i) more management changes, ii) strategic shift including licensing certain technologies, iii) possibility of the company being sold

* Stock looks very cheap at current prices

* Waiting on the sidelines for now, but given the management change is starting to look at it again. Waiting to see what "the plan" is before getting back in

Bullboard Posts

How one company is disrupting PoC testing